Background: The identification of Brucella isolates using conventional microbiological techniques is time-consuming and hazardous. We therefore assessed the performance of real-time PCR assays for the identification of members of the genus Brucella to the genus and species level. Methods: We evaluated an in-house developed assay and various previously published real-time PCR assays targeting bcsp31, per, IS711, alkB/IS711 and BMEI1162/IS711 using 248 Brucella strains representing the biotypes of all species and a large panel of clinically relevant, phylogenetically related and serologically cross-reacting bacteria. Results: No misidentification was observed. However, several biotypes of Brucella abortus and Brucella suis were not detected with some of the published assays. The limit of detection varied widely among the assays (16-1600 fg) demonstrating that some assays should not be applied to clinical samples but may help to identify colony material. Conclusions: In summary, most of the assays revealed low detection limits and proved to be highly selective for the detection of the genus Brucella and the species that are most relevant for humans. Assays targeting the bcsp31 gene can be recommended to screen for Brucella. Species-specific assays should be consecutively applied confirming the primary diagnosis by a second gene target. Clin Chem Lab Med 2007;45:1464-70. 
Introduction
Brucellosis is a re-emerging zoonosis caused by genetically and phenotypically closely related species of the genus Brucella (B.). Four out of six species are pathogenic for humans, i.e., B. abortus, B. melitensis, B. suis and B. canis. Human brucellosis may present as an acute flu-like disease with intermittent fever, chills, weakness and weight loss. A chronic course and primary treatment failure with disease relapse frequently occur. Although many organ systems can be involved leading to focal complications, brucellosis is rarely fatal. However, patients with brucellosis are disabled for weeks to months and require prolonged antibiotic therapy. In the livestock industry, brucellosis can also lead to substantial economic losses and its eradication is challenging. For all these reasons, Brucella species were among the first microorganisms weaponized as biological warfare agents in the 1950s. In this context, brucellosis has recently attracted attention, since Brucella is endemic and readily available in many countries and might be used in bioterrorist attacks.
The diagnostic gold standard confirming active brucellosis is culturing the fastidious bacterium which requires several days or even weeks. The yield of positive blood cultures ranges from 15% to 75% (1) . The identification of Brucella species and biotypes is based on CO 2 requirement, H 2 S production, urease activity, agglutination with specific sera (A and M), selective inhibition of growth on media containing dyes such as thionin or basic fuchsin, and phage typing. These procedures are time-consuming, hazardous and subject to variable interpretation. Serological tests are therefore commonly used but cross-reactions with various bacteria, e.g., Yersinia and Francisella, as well as false-negative results have been reported (2) . DNA-based techniques for species identification are challenging owing to the high genetic homology among Brucella species exceeding 90% (3). The multiplex AMOS-PCR was a first approach towards the differentiation of four Brucella species, i.e., B. abortus, B. melitensis, B. ovis and B. suis (4, 5) . Recently, García-Yoldi and colleagues were able to develop a conventional multiplex PCR assay for the identification of all Brucella species and some vaccine strains (6) .
Real-time PCR constitutes a further technological improvement for the molecular identification of the genus Brucella and the differentiation of its species. The real-time PCRs established by Redkar et al. (7), Newby et al. (8) , Probert et al. (9) and Bogdanovich et al. (10) were described as rapid, sensitive and specific diagnostic tools with a low risk of cross-contamination and the potential of automation. Different studies describing genus-specific real-time PCR assays applied to human specimens, e.g., serum, urine samples, cerebrospinal fluids, have been published (11) (12) (13) (14) (15) (16) . However, quality control requires the comprehensive evaluation of nucleic acid amplification assays prior to their application in the clinical laboratory (17) . To the best of our knowledge, neither independent evaluation nor direct comparison of these assays has been performed.
The aim of this study was to evaluate various realtime PCR assays for the rapid, sensitive and specific identification of Brucella species. The performance of previously published assays was compared to our newly developed genus-specific real-time PCR assay, which includes an internal amplification control especially useful for clinical samples.
Materials and methods

Bacteria and DNA samples
A comprehensive collection of 248 Brucella field isolates and reference strains comprising all currently known species and biotypes were used for the evaluation of real-time PCR assays (Tables 1 and 2 ). The genus-specific PCRs were additionally tested with a panel of clinically relevant, potentially cross-reacting and phylogenetically related bacteria (Table  3) . Brucella spp. were cultured under biosafety level 3 conditions and characterized by classical microbiological methods according to Alton et al. (18) . After inactivation in 10% (vol/vol) formalin overnight, the bacterial pellets were washed twice in phosphate buffered saline. DNA used to assess the detection limits of assays was purified using a HighPure PCR Template Preparation Kit (Roche Diagnostics, Mannheim, Germany; cat. no. 1796828). Subsequently, the concentration of DNA was determined photometrically using a NanoDrop ᮋ ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
Real-time PCR assays
Our standard in-house real-time PCR is based on the primer pair B4 (TGGCTCGGTTGCCAATATCAA) and B5 (CGCGCTT-GCCTTTCAGGTCTG) published by Baily et al. (19) and hybridization probes BruFL (AGGCAACGTCTGACTGCG-TAAAGCC) and BruLC (LC Red640-ACTCCAGAGCGCCC-GACTTGATCG) designed in cooperation with and obtained from TIB MOLBIOL (Berlin, Germany). The gene target amplified in our assay encodes for an immunogenic Brucellaspecific 31-kDa outer membrane protein. As an internal amplification control, we included a bacteriophage l-PCR system as described previously (20) . Briefly, a single tube duplex LightCycler ᮋ -PCR was performed using a LightCycler FastStart DNA Master Hybridization Probes Kit (Roche Diagnostics). The 20-mL reaction mixture contained 2.5 mM MgCl 2 , 2 mL 10= reaction mix, 0.5 mL of each primer (20 pmol/mL), 0.5 mL of each hybridization probe (8 pmol/mL) and 2 mL of template DNA. No template controls containing 2 mL of molecular grade water instead of DNA and positive controls containing Brucella DNA of the reference strains B. melitensis 16M (bv1), B. abortus 1119-3 (bv1) and/or B. suis 1330 (bv1) were included in each run to detect any amplicon contamination or amplification failure. All samples were tested in duplicate. Cycling was started with a 10-min denaturation step at 958C followed by 45 cycles with 10 s of denaturation at 958C, 10 s for annealing at 558C and 12 s for extension at 728C. Temperature transition rates were set at 208C s
y1
. Fluorescence values were measured during each cycle at 640 nm and 705 nm to detect specific target and internal amplification control, respectively. Melting curves were generated by continuous measurement of fluorescence while raising the temperature from 458C to 958C with a transition rate of 0.28C s y1 . Data analysis was performed using LightCycler ᮋ software version 3.32 (Roche Diagnostics). The 2nd derivative maximum algorithm was used to calculate the cycle threshold (C T ) value. Positive results were confirmed by visual inspection of the graphical plots showing cycle numbers vs. fluorescence values. A negative result was assigned when no amplification occurred or the C T value was higher than 40 cycles.
All other assays were performed as described previously (Table 4 ). Modifications were made with regard to the realtime PCR equipment available in our laboratory as described below. However, real-time PCR assays for the detection of biologic threat agents can be easily transferred from one technical platform to another (21).
Redkar et al. (7) described real-time LightCycler
ᮋ
-PCR assays for B. abortus, B. melitensis and B. suis targeting the insertion element IS711 and using species-specific reverse primers and hybridization probes.
Probert et al. (9) developed 59-nuclease assays targeting the bcsp31 gene for the identification of the genus Brucella, the specific insertion of an IS711 element downstream of the alkB gene for the identification of B. abortus and the specific insertion of an IS711 element downstream of BMEI1162 for the identification of B. melitensis. These targets are similar to those described by Redkar et al. (7), but primers and probes were redesigned for use in a multiplex format. The assays were established on an iCycler ᮋ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). We used an ABI Prism ᮋ 7000 Sequence Detection System (Applera, Darmstadt, Germany) instead.
Newby et al. (8) compared SYBR green I, 59-exonuclease and hybridization probes assays for the detection of B. abortus targeting portions of the alkB gene and the IS711 element. These assays were originally evaluated on a R.A.P.I.D.
ᮋ Cycler (Ruggedized Advanced Pathogen Identification Device, Idaho Technology, Salt Lake City, UT, USA), which is a robust portable field-version of the LightCycler ᮋ instrument. In this study, we only evaluated the 59-exonuclease assay as it allows simultaneous detection of reactions in a 96-well plate format.
Bogdanovich et al. (10) developed a 59-nuclease assay for the identification of the genus Brucella targeting the perosamine synthetase gene (per). The reaction mix used in the original study was an optimized composition of all basic reagents and was prepared in-house. The assay included an internal amplification control and was performed using a RotorGene ᮋ 3000 (Corbett Research, Mortlake, Australia). We used an ABI Prism ᮋ 7000 Sequence Detection System and a ready-to-use TaqMan Universal MasterMix (Applera, Darmstadt, Germany) to evaluate this assay. Although the in-house prepared mastermix may be more economical, we preferred the ready-to-use MasterMix which reduces the risk of pipetting errors and improves the reproducibility of the assay.
Analytical sensitivity
In accordance with the evaluation scheme presented by Bogdanovich et al. (10) , an approximate estimation of detection limits was calculated using serial logarithmic dilutions of Brucella DNA in triplicates. The detection limit was defined Table 1 Number of Brucella strains detected by genus-specific and species-specific PCR assays published by Redkar et al. (7) as the lowest amount of DNA that was consistently detected in these dilution series.
Results
Sensitivity
The results obtained with the different real-time PCR assays by testing various Brucella spp. are given in Table 1 . The Brucella genus-specific real-time PCR assays targeting bcsp31 detected all Brucellae. The melting temperature of our in-house assay was 68"28C. The detection limit was not influenced by the internal amplification control (data not shown 
Specificity
All non-Brucella strains tested negative with the Brucella-specific PCR assays evaluated in this study (Table 3) .
Analytical limit of detection
Assuming a DNA content of 3-5 fg per bacterial cell, approximately five bacteria per reaction were detected using most of the assays evaluated in this study.
Only the Brucella genus-specific assay described by Bogdanovich et al. (10) displayed a higher limit of detection: 1.6 pg and 50 pg per reaction for B. melitensis and B. abortus, respectively ( Table 1 ). The analytical sensitivity of the genus-specific assays varied depending on the species.
Discussion
In the diagnosis of human brucellosis time-consuming culture and phenotypic characterization of the isolate is the gold standard. However, the low yield of Brucella cultures often results in diagnostic delay and the late initiation of appropriate antibiotic treatment. Serology is a more effective means for diagnosis, although cross-reactivity in the setting of other bacterial infections is still a major problem. Real-time PCR has proved to be a valuable tool when culture fails or serological results are inconclusive (14) , and in addition, a test result can be available within a few hours. Consequently, we assessed the performance of previously published real-time PCR assays (7-10) to evaluate their potential role for diagnostic purposes. Furthermore, we tested our genus-specific in-house assay which includes an internal amplification control.
Both hybridization probes and 59-exonuclease assays were evaluated, because each format has valuable features. Since the detection via hybridization probes does not depend on a hydrolysis reaction, a melting curve analysis can be performed to verify a specific amplicon by its characteristic melting temperature. 59-Exonuclease assays are more useful for large-scale screening as most of the instrument platforms that use this detection format allow for the assessment of 96 or even 384 samples in parallel and the simultaneous detection of several targets when needed. We encountered no difficulties when we transferred the previously described real-time PCR assays to our instrument platforms. However, we were not readily able to perform the 59-nuclease assay for the identification of B. abortus established for the LightCycler ᮋ platform by Newby et al. (8) on other real-time PCR instruments (data not shown).
Redkar's real-time PCR assays (7) are based on the AMOS-PCR developed by Bricker and Halling (4), and are therefore expected to be restricted to the detection of B. abortus bv1, -2 and -4, B. melitensis and B. suis bv1. This is in accordance with our results except for the additional detection of a single B. abortus bv6 strain. The detection of the three B. melitensis biotypes which are known to be responsible for the vast majority of human infections worldwide was reliable.
Sensitivity, specificity and analytical sensitivity of Probert's real-time PCR assay (9) for the identification of B. melitensis isolates were identical to those of Redkar's assay (7). The B. abortus-specific assays evaluated in this study showed only minor differences. The assay developed by Probert et al. (9) had the highest sensitivity and was even able to detect some of the B. abortus bv3 isolates. Bogdanovich et al. (10) tested their 59-nuclease per gene PCR assay with a large panel of non-Brucella strains proving its high specificity. However, only 23 Brucella reference strains were tested. In this study, this assay was unable to detect some B. ovis and many B. maris field isolates.
The detection limit of the Brucella genus-specific real-time PCR assays varied depending on the species (Table 1) . Assuming a molecular mass of the Brucella genome of approximately 3 fg DNA (8, 19) , the detection limit of the tested real-time PCR assays was approximately five genome equivalents. The detection limit of the per-based assay proved to be exceptionally high (1.6 pg per reaction) which is why Bogdanovich et al. (10) suggested that their assay can only be used for the identification of Brucella colonies, but should not be applied to clinical samples. Debeaumont et al. (12) tested serum samples of brucellosis patients for their bacterial DNA load using a quantitative bcsp31-based real-time PCR. Approximately 25-650 genomic copies/5 mL of DNA extract were found. Hence, the detection limits assessed in this study indicate the potential usefulness of most assays for direct detection of Brucella DNA in clinical specimens.
In our in-house real-time PCR, we used the bcsp31 gene encoding a 31-kDa immunogenic outer membrane protein conserved among Brucella spp. as target. It is the most frequently described PCR target for the diagnosis of human brucellosis. In serum samples collected from patients with active infection, a bcsp31-based real-time PCR assay using LightCycler ᮋ technology with SYBR green I proved to be 91.9% sensitive and 95.4% specific (14) . Applying the same technique to urine samples, nine out of ten patients suffering from Brucella epididymo-orchitis tested positive, whereas Brucella could only be cultured from one of the collected urine samples (15) . Colmenero et al. (13) were able to isolate the bacterium from two out of six cerebrospinal fluid (CSF) samples of neurobrucellosis cases, whereas Brucella DNA was easily detected in all six CSF samples by the assay described above. In patients with focal disease and after the application of antimicrobial agents, PCR has proven to be more sensitive than culture (22) . Although a positive real-time PCR result cannot prove an active infection caused by the living agent, the onset of antibiotic therapy is justified since Brucella is obligate pathogenic with a high rate of sequelae if untreated. It has to be investigated in the future whether or not the persistence of DNA is indicative of a latent or chronic infection. Additionally, real-time PCR techniques may facilitate the quantification of nucleic acids which can be used to monitor the Brucella DNA load in blood samples of brucellosis patients under therapy and during post-treatment follow-up (11) . Damaged, non-viable and dormant bacteria which may occur after the initiation of treatment remain detectable. Using a primer set spanning a B. melitensis-specific region and the IS711 insertion element, Navarro et al. (11) showed that the DNA load in brucellosis patients sharply decreased after initiating antimicrobial therapy. Realtime PCR reliably detected Brucella DNA in clinically relapsed but culture negative patients. However, low bacterial DNA loads persisted in some asymptomatic non-relapsed patients for more than 10 months of follow-up, reflecting the chronic nature of the disease. Hence, the monitoring of DNA load may not be helpful in predicting a relapse.
Finally, the diagnosis of human brucellosis can be markedly improved by using standardized protocols, evaluated reagents and an internal amplification control for testing clinical samples. Especially in the context of potential bioterrorism-related outbreaks, real-time PCR will allow rapid high-throughput screening of samples.
Based on our results, we can recommend the assays targeting the bcsp31 gene to screen for Brucella when clinical signs and symptoms are suggestive for the disease or in cases of fever of unknown origin. This may help to avoid false negative results caused by rare species and biotypes. In addition, an appropriate antimicrobial therapy which is identical for all members of the genus Brucella can be immediately initiated. A species-specific assay should be consecutively applied keeping the epidemiological background in mind. Thus, a second gene target will confirm the diagnosis. For this purpose, the assays described by Redkar et al. (7) and Probert et al. (9) for the identification of B. melitensis can be recommended. B. abortus-specific assays tested in this study will be able to identify the most frequent biotypes. Due to the paucity of data for B. suis, recommendations concerning its detection cannot be made. However, conventional multiplex PCR assays are still valuable tools that can accelerate the identification of Brucella strains to the species level (4-6).
In our experience, inhibition of the PCR reaction in clinical samples occurs quite frequently, which demands the use of an amplification control. In comparison with serum, whole blood samples presumably contain higher bacterial cell counts, but inhibitors may be more prevalent (23) . Dilution of the samples may reduce the inhibitory effect of the sample matrix, but the generally small amount of DNA in clinical samples is challenging even for assays with a very low detection limit. We therefore suggest testing several replicates of the purified DNA from clinical specimens in parallel to increase the probability of a positive result.
Our comprehensive evaluation of real-time PCRs with a large panel of bacteria should help routine laboratories to decide which molecular assay is most appropriate for their needs.
